ADMA Biologics, Inc. (ADMA)

NASDAQ • Healthcare

$10.36

+$0.02 (+0.3%)

Market closed

Last close at October 9, 2026 at 20:00 UTC

Open$10.32

Day Range$10.25 - $10.51

Avg. Volume (3M)3.4M

Market Cap$2.4B

P/E Ratio14.4

52 Week Range

$7.21$20.46

Next EarningsIn 25 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$124.3M100%

Gross Profitminus cost of goods$86.2M69%

Operating Incomeminus R&D and overhead$52.4M42%

Net Incomeminus taxes and the rest$37.8M30%

In plain terms: out of every $100 in revenue, ADMA Biologics, Inc. keeps $30 as net profit.

Fundamentals & Financials

Revenue (TTM)

$512.2M

Net Income (TTM)

$168.9M

EPS (TTM)

$0.72

ROA (TTM)

24.69%

Current Ratio

6.97

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+7.1%Q3 2025$0.15

0.0%Q4 2025$0.16

+8.1%Q1 2026$0.2

-1.7%Q2 2026$0.19

-2.0%Q3 2026$0.16

Nov 4

in 25 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -2.0%

ADMA Biologics missed consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, reported Aug. 5, even as revenue rose 2.0% to about $124.4 million. Gross margin held near 69% and operating margin around 42%, with operating income at about $52.4 million and net income rising 10.5% to about $37.8 million from about $34.2 million a year ago. Adjusted EPS was $0.16 versus the $0.16 estimate, a -2.0% miss, and operating cash flow came in at about $87.8 million. Consensus for the next period calls for EPS of $0.19 on revenue of $139.0 million.

Next report — what to expect

ADMA Biologics, Inc. (ADMA) is set to report earnings on November 4, 2026. Wall Street’s next-period consensus calls for EPS of $0.19 on revenue of $138.1 million. For trailing context, revenue was +2.0% year over year last quarter. ADMA has beaten EPS in 3 of 8 most recent quarters.

View full earnings history

About ADMA Biologics, Inc.

ADMA Biologics, Inc. (NASDAQ: ADMA) is a healthcare biotechnology company that develops, manufactures, and commercializes plasma-derived biologic therapies. Its business centers on immune globulin and hepatitis B products sold in the United States and abroad, and it generated $510.2 million of revenue in FY2025.

Name

ADMA Biologics, Inc.

CEO

Adam S. Grossman

Website

www.admabiologics.com

Industry

Healthcare

Year Founded

2004

Employees

644

Today's Snapshot

AI-generated

ADMA closed slightly higher at 10.36, while its sector was firmer. ADMA Biologics abruptly replaced its outside financial auditor.

Trading Volume

Below 10d avg (3.2M)

2.7M

vs S&P 500 Today

Moderate Underperformance

-0.30%

Updated: October 9, 2026 at 20:10 UTC

ADMA Headlines

Valuation Shifts In Major Healthcare Stocks

March 25, 2026

5 min read

View All News

Technical Indicators

5 Buy1 Neutral2 Sell

ADMA displays constructive near-term technicals while longer-term resistance remains relevant. The shares trade around $10.36 and sit above short- and medium-term moving averages, supported by positive MACD and a strong CCI, while RSI is mildly bullish. ADX near 19 indicates limited trend strength and ATR is moderate, so momentum gains are not yet emphatic, and the price remains below the 200-day averages, which temper the upside. On-balance volume shows buying interest despite the longer-term hurdle. Technical takeaway: the technicals skew to buy.

All signals

EMA (5 indicators)$9.58 - $11.86
Buy
RSI (14)62.89
Neutral
Stochastic %K (14, 3, 3)88.70
Sell
MACD Level (12, 26)0.24
Buy

Peers & Related Assets

ABUSArbutus Biopharma Corp

$4.22+1.0%

GRFSGrifols, S.A.

IVVDInvivyd, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.